tirzepatide fda news The approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in patients with obesity after research showed that the medication improved outcomes in these patients. Sleep apnea https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and
Pay in 4 interest-free payments of $7.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16




























